MPIE operates in the areas of research and development (R&D), manufacturing, and distribution of pharmaceuticals. It holds a domestic market share ranging from 3% to 10% and exports snake antivenoms to neighboring countries such as Cambodia and Laos.
MPIE operates 3 state-owned pharmaceutical factories across Myanmar: Insein, Yangon Region; Inyaung, Kyaukse District, Mandalay Region; and Ywathagyi, Hlegu District, Yangon Region.
In recent years, Myanma Pharmaceutical Industrial Enterprise (MPIE) has taken significant strides such as expanding its product line, including the production of vaccines and antibiotics. The export market for snake antivenoms has also been expanded. Since 2017, MPIE produced 170 different pharmaceutical products, with a total value of 30 billion Kyats. With the value production increasing by over 63% the following year, reaching 49 billion Kyats, MPIE’s market share rose to 15%.
Looking towards the future direction, MPIE has announced plans to manufacture cancer and HIV drugs, as well as rabies vaccines. MPIE is also returning to using the brand “BPI” instead of “MPF,” the abbreviation of Myanmar Pharmaceutical Factory, introduced by the military regime.
The factories are currently producing snake antivenoms in dried form, which can be stored for 5 years in rural areas without electricity.
The factory also procures necessary items for snake antivenom production such as horse and snake serum, alongside approximately 500 breeding horses for research purposes. As of the current time, BPI/MPF exports 200,000 snake antivenom medicines to Southeast Asian countries annually.
